A Phase 3, Randomized, Modified Double-blind, 2-arm Study to Evaluate the Immunogenicity and Safety of High-Dose Inactivated Influenza Vaccine (IIV-HD) Compared With a Standard-dose Inactivated Influenza Vaccine (IIV-SD) in Participants 50 Through 64 Years of Age.

The purpose of this study is to evaluate Immunogenicity and Safety of a High-Dose (HD) Influenza Vaccine (IV) in Adults 50 through 64 Years of Age.

Start Date04 Nov 2024

Sponsor / Collaborator

Sanofi Pasteur

NCT05514002

/ TerminatedPhase 4IIT

Randomized Participant- and Investigator-Blinded Trial to Compare the Clinical Efficacy of Recombinant Influenza Vaccine to Standard Dose Egg-Based Inactivated Influenza Vaccine Among Adults Aged 18-64 Years in the United States

This randomized, active comparator trial will compare the clinical efficacy of recombinant influenza vaccine (RIV) to standard-dose egg-based inactivated influenza vaccine (SD IIV) among adults aged 18-64 years. The primary study hypothesis is that the clinical efficacy of RIV is superior to that of SD IIV to prevent and attenuate influenza-like illness (ILI)-associated influenza virus infection. Relative efficacy will be assessed by comparing rates of ILI-associated reverse transcription polymerase chain reaction (RT-PCR)-confirmed influenza virus infection and measures of infection and illness attenuation among participants who receive RIV versus SD IIV. A secondary hypothesis is that humoral and cell-mediated immune responses to RIV are superior to responses to SD IIV. Relative immunogenicity will be assessed by comparing markers of humoral and cell-mediated immune responses post-vaccination among a subset of participants who receive RIV versus SD IIV.

Start Date13 Sep 2022

Sponsor / Collaborator

Centers for Disease Control & Prevention

[+5]

CTR20191860

/ CompletedPhase 1

在中国 40名健康成年受试者中的I期、开放、单组、单中心的评估肌肉注射Flublok四价流感疫苗的安全性研究

[Translation] A Phase I, open-label, single-group, single-center study evaluating the safety of intramuscular Flublok quadrivalent influenza vaccine in 40 healthy adult subjects in China

研究目的是描述所有受试者的安全性特征。

[Translation]

The study objective was to describe the safety characteristics of all subjects.

Start Date16 May 2020

Sponsor / Collaborator

Shenzhen Sanofi Pasteur Biological Products Co. Ltd.

100 Clinical Results associated with Influenza vaccine(Protein Sciences Corp.)

100 Translational Medicine associated with Influenza vaccine(Protein Sciences Corp.)

100 Patents (Medical) associated with Influenza vaccine(Protein Sciences Corp.)

1,048

Literatures (Medical) associated with Influenza vaccine(Protein Sciences Corp.)

01 Mar 2025·RöFo - Fortschritte auf dem Gebiet der Röntgenstrahlen und der bildgebenden Verfahren

Vaccine-associated axillary lymphadenopathy with a focus on COVID-19 vaccines

Article

Author: Weigel, Stefanie ; Wessling, Daniel ; Wenkel, Evelyn ; Wilpert, Caroline ; Preibsch, Heike ; Baltzer, Pascal Andreas Thomas ; Siegmann-Luz, Katja ; Wunderlich, Petra ; Sauer, Stephanie Tina ; Fallenberg, Eva Maria

AbstractAxillary lymphadenopathy (LA) after COVID-19 vaccination is now known to be a common side effect. In these cases, malignancy cannot always be excluded on the basis of morphological imaging criteria.Narrative review for decision-making regarding control and follow-up intervals for axillary LA according to currently published research. This article provides a practical overview of the management of vaccine-associated LA using image examples and a flowchart and provides recommendations for follow-up intervals. A particular focus is on patients presenting for diagnostic breast imaging. The diagnostic criteria for pathological lymph nodes (LN) are explained.Axillary LA is a common adverse effect after COVID-19 vaccination (0.3–53%). The average duration of LA is more than 100 days. LA is also known to occur after other vaccinations, such as the seasonal influenza vaccine. Systematic studies on this topic are missing. Other causes of LA after vaccination (infections, autoimmune diseases, malignancies) should be considered for the differential diagnosis. If the LA persists for more than 3 months after COVID-19 vaccination, a primarily sonographic follow-up examination is recommended after another 3 months. A minimally invasive biopsy of the LA is recommended if a clinically suspicious LN persists or progresses. In the case of histologically confirmed breast cancer, a core biopsy without a follow-up interval is recommended regardless of the vaccination, as treatment appropriate to the stage should not be influenced by follow-up intervals. For follow-up after breast cancer, the procedure depends on the duration of the LA and the woman’s individual risk of recurrence.Vaccination history should be well documented and taken into account when evaluating suspicious LN. Biopsy of abnormal, persistent, or progressive LNs is recommended. Preoperative staging of breast cancer should not be delayed by follow-up. The risk of false-positive findings is accepted, and the suspicious LNs are histologically examined in a minimally invasive procedure.

05 Feb 2025·mBio

Are we serologically prepared against an avian influenza pandemic and could seasonal flu vaccines help us?

Article

Author: Sánchez-Martínez, Javier ; Domínguez-Gil, Marta ; Hernández, Marta ; Nogales, Aitor ; Martinez-Sobrido, Luis ; Rojo-Rello, Silvia ; Concha-Santos, Corina S. ; Rodríguez-Crespo, Carla ; Mostafa, Ahmed ; Eiros, Jose M. ; Sanz-Muñoz, Iván

ABSTRACTThe current situation with H5N1 highly pathogenic avian influenza virus (HPAI) is causing a worldwide concern due to multiple outbreaks in wild birds, poultry, and mammals. Moreover, multiple zoonotic infections in humans have been reported. Importantly, HPAI H5N1 viruses with genetic markers of adaptation to mammals have been detected. Together with HPAI H5N1, avian influenza viruses H7N9 (high and low pathogenic) stand out due to their high mortality rates in humans. This raises the question of how prepared we are serologically and whether seasonal vaccines are capable of inducing protective immunity against these influenza subtypes. An observational study was conducted in which sera from people born between years 1925–1967, 1968–1977, and 1978–1997 were collected before or after 28 days or 6 months post-vaccination with an inactivated seasonal influenza vaccine. Then, hemagglutination inhibition, viral neutralization, and immunoassays were performed to assess the basal protective immunity of the population as well as the ability of seasonal influenza vaccines to induce protective responses. Our results indicate that subtype-specific serological protection against H5N1 and H7N9 in the representative Spanish population evaluated was limited or nonexistent. However, seasonal vaccination was able to increase the antibody titers to protective levels in a moderate percentage of people, probably due to cross-reactive responses. These findings demonstrate the importance of vaccination and suggest that seasonal influenza vaccines could be used as a first line of defense against an eventual pandemic caused by avian influenza viruses, to be followed immediately by the use of more specific pandemic vaccines.IMPORTANCEInfluenza A viruses (IAV) can infect and replicate in multiple mammalian and avian species. Avian influenza virus (AIV) is a highly contagious viral disease that occurs primarily in poultry and wild water birds. Due to the lack of population immunity in humans and ongoing evolution of AIV, there is a continuing risk that new IAV could emerge and rapidly spread worldwide, causing a pandemic, if the ability to transmit efficiently among humans was gained. The aim of this study is to analyze the basal protection and presence of antibodies against IAV H5N1 and H7N9 subtypes in the population from different ages. Moreover, we have evaluated the humoral response after immunization with a seasonal influenza vaccine. This study is strategically important to evaluate the level of population immunity that is a major factor when assessing the impact that an emerging IAV strain would have, and the role of seasonal vaccines to mitigate the effects of a pandemic.

04 Feb 2025·The Journal of Infectious Diseases

Safety and Immunogenicity of mRNA-1010, an Investigational Seasonal Influenza Vaccine, in Healthy Adults: Final Results From a Phase 1/2 Randomized Trial

Article

Author: Carmona, Lizbeth ; Huang, Wenmei ; Chen, Ren ; Avanesov, Andrei ; Paris, Robert ; Nachbagauer, Raffael ; Kuo, Hsiao-Hsuan ; Ananworanich, Jintanat ; Lee, Ivan T ; Ensz, David ; Choi, Angela ; Henry, Carole ; Stadlbauer, Daniel ; Pucci, Alicia ; McGrath, Shannon ; Schaefers, Kristi

AbstractBackgroundSeasonal influenza remains a global public health concern. A messenger RNA (mRNA)–based quadrivalent seasonal influenza vaccine, mRNA-1010, was investigated in a first-in-human, phase 1/2 clinical trial conducted in 3 parts.MethodsIn parts 1 to 3 of this stratified observer-blind study, adults aged ≥18 years were randomly assigned to receive a single dose (6.25–200 µg) of mRNA-1010 or placebo (part 1) or an active comparator (Afluria; parts 2 and 3). Primary study objectives were assessment of safety, reactogenicity, and humoral immunogenicity of mRNA-1010, placebo (part 1), or active comparator (parts 2 and 3). Exploratory end points included assessment of cellular immunogenicity (part 1) and antigenic breadth against vaccine heterologous strains (A/H3N2; parts 1 and 2).ResultsIn all study parts, solicited adverse reactions were reported more frequently for mRNA-1010 than placebo or Afluria, and most were grade 1 or 2 in severity. No vaccine-related serious adverse events or deaths were reported. In parts 1 and 2, a single dose of mRNA-1010 (25–200 µg) elicited robust day 29 hemagglutination inhibition titers that persisted through 6 months. In part 3, lower doses of mRNA-1010 (6.25–25 µg) elicited day 29 hemagglutination inhibition titers that were higher or comparable to those of Afluria for influenza A strains. When compared with Afluria, mRNA-1010 (50 µg) elicited broader A/H3N2 antibody responses (part 2). mRNA-1010 induced greater T-cell responses than placebo at day 8 that were sustained or stronger at day 29 (part 1).ConclusionsData support the continued development of mRNA-1010 as a seasonal influenza vaccine.Clinical Trials RegistrationNCT04956575 (https://clinicaltrials.gov/study/NCT04956575).

News (Medical) associated with Influenza vaccine(Protein Sciences Corp.)

14 Mar 2025

·www.prnewswire.com

Sanofi adopts FDA-selected flu strains to ensure readiness for the 2025-26 flu season

BRIDGEWATER, N.J., March 14, 2025 /PRNewswire/ -- Sanofi announced today the immediate adoption of influenza strains selected by the US Food and Drug Administration (FDA) to advance the manufacturing and delivery of its vaccine portfolio for the 2025-26 flu season in the US. As the world leader in flu vaccines, Sanofi had already begun its annual production of vaccines to ensure that robust supply is ready for the coming season. Strains selected by the FDA match those already used in production by the company to help protect eligible patients against flu and its potentially severe complications. Sanofi plans to begin shipping flu vaccines this summer so that health systems, hospitals, pharmacies, physician practices, nursing homes and other facilities can begin administering vaccines at the onset of the next flu season. Thomas Grenier Head of Vaccines, North America "The US is weathering one of its most severe flu seasons in decades, underscoring the need to protect people against seasonal influenza infection. As the world leader in flu vaccines, Sanofi works relentlessly to ensure we are prepared, which is why our manufacturing does not miss a beat as we provide eligible Americans with a portfolio of immunizations to help protect against flu infection and the potentially serious complications it can cause." In addition to declining vaccination rates, the US is currently experiencing one of the worst flu seasons in decades and rates of flu-related hospitalizations are at a 15-year high. According to estimates by the US Centers for Disease Control and Prevention, there have been 40 million illnesses, 520,000 hospitalizations and 22,000 deaths from flu through the week ending March 1. Public health authorities nationwide recommend eligible people six months of age and older be vaccinated every year to help protect against flu and its complications. Sanofi offers a range of vaccine options supported by extensive data to help protect eligible patients from flu and its complications, providing protection beyond flu by meeting immunization needs across the lifespan, from children as young as six months of age through adults 65 years of age and older. The 2025-26 US influenza season portfolio will include FLUZONE® High-Dose (Influenza Vaccine), FLUBLOK® (Influenza Vaccine) and FLUZONE® (Influenza Vaccine). Indication and Important Safety Information for FLUZONE® High-Dose (Influenza Vaccine), FLUBLOK® (Influenza Vaccine) and FLUZONE® (Influenza Vaccine) What are FLUZONE® (Influenza Vaccine), FLUBLOK® (Influenza Vaccine), and FLUZONE® High-Dose (Influenza Vaccine)? FLUZONE, FLUBLOK, and FLUZONE HIGH-DOSE are vaccines indicated for the prevention of disease caused by influenza A and B strains contained (or in the case of FLUBLOK, represented by antigens contained in) the vaccine. FLUZONE is given to people 6 months of age and older. FLUBLOK is given to people 18 years of age and older. FLUZONE HIGH-DOSE is given to people 65 years of age and older. IMPORTANT SAFETY INFORMATION FOR FLUZONE® (INFLUENZA VACCINE), FLUBLOK® (INFLUENZA VACCINE), AND FLUZONE® HIGH-DOSE (INFLUENZA VACCINE) FLUZONE, FLUBLOK, or FLUZONE HIGH-DOSE should not be given to anyone who has had a severe allergic reaction to any component of the vaccine (including eggs or egg products for FLUZONE and FLUZONE HIGH-DOSE). In addition, FLUZONE and FLUZONE HIGH-DOSE should not be given to anyone who has had a severe allergic reaction after a previous dose of any influenza vaccine. Tell your health care provider if you have ever had Guillain-Barré syndrome (severe muscle weakness) after a previous influenza vaccination. If FLUZONE, FLUBLOK, or FLUZONE HIGH-DOSE are given to people with a compromised immune system, including those receiving therapies that suppress the immune system, the immune response may be lower than expected. Vaccination with FLUZONE, FLUBLOK, or FLUZONE HIGH-DOSE may not protect all people who receive the vaccine. Fainting has occurred following vaccination with FLUZONE, FLUBLOK, and FLUZONE HIGH-DOSE. Procedures should be in place to avoid injury from fainting. For FLUZONE, in children 6 months through 8 years of age, the most common side effects were pain or tenderness and redness where you got the shot, irritability, drowsiness (6 month through 35 months), and muscle pain (3 years through 8 years). In adults 18 years through 64 years of age, the most common side effects were pain where you got the shot, headache, and muscle pain. In adults over 65 years of age, the most common side effects were pain where you got the shot, headache, muscle pain, and general discomfort. For FLUBLOK, in adults 18 through 64 years of age, the most common side effects were pain where you got the shot, headache, tiredness, and muscle pain. In adults 65 years of age and older, the most common side effects were pain where you got the shot, tiredness, and headache. For FLUZONE HIGH-DOSE, in adults 65 years of age and older, the most common side effects were pain where you got the shot, muscle pain, tiredness, and headache. For FLUZONE, FLUBLOK, and FLUZONE HIGH-DOSE, other side effects may occur. For more information, talk to your healthcare professional and refer to the full Prescribing and Patient information for FLUBLOK, FLUZONE or FLUZONE HIGH-DOSE. About Sanofi We are an innovative global healthcare company, driven by one purpose: we chase the miracles of science to improve people's lives. Our team, across the world, is dedicated to transforming the practice of medicine by working to turn the impossible into the possible. We provide potentially life-changing treatment options and life-saving vaccine protection to millions of people globally, while putting sustainability and social responsibility at the center of our ambitions. Sanofi is listed on EURONEXT: SAN andNASDAQ: SNY Media Relations Evan Berland | +1 215 432 0234 | [email protected] Timothy Gilbert | + 1 516 521 2929 | [email protected] Investor Relations Thomas Kudsk Larsen |+44 7545 513 693 | [email protected] Alizé Kaisserian | +33 6 47 04 12 11 | [email protected] Felix Lauscher | +1 908 612 7239 | [email protected] Keita Browne | +1 781 249 1766 | [email protected] Nathalie Pham | +33 7 85 93 30 17 | [email protected] Tarik Elgoutni | +1 617 710 3587 | [email protected] Thibaud Châtelet | +33 6 80 80 89 90 | [email protected] Yun Li | +33 6 84 00 90 72 | [email protected] Sanofi forward-looking statements This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates regarding the marketing and other potential of the product, or regarding potential future revenues from the product. Forward-looking statements are generally identified by the words "expects", "anticipates", "believes", "intends", "estimates", "plans", and similar expressions. Although Sanofi's management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, unexpected regulatory actions or delays, or government regulation generally, that could affect the availability or commercial potential of the product, the fact that product may not be commercially successful, the uncertainties inherent in research and development, including future clinical data and analysis of existing clinical data relating to the product, including post marketing, unexpected safety, quality or manufacturing issues, competition in general, risks associated with intellectual property and any related future litigation and the ultimate outcome of such litigation, and volatile economic and market conditions, and the impact that global crises may have on us, our customers, suppliers, vendors, and other business partners, and the financial condition of any one of them, as well as on our employees and on the global economy as a whole. The risks and uncertainties also include the uncertainties discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under "Risk Factors" and "Cautionary Statement Regarding Forward-Looking Statements" in Sanofi's annual report on Form 20-F for the year ended December 31, 2024. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements. SOURCE Sanofi WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

VaccineDrug Approval

12 Dec 2024

·www.pharmaceutical-technology.com

Sanofi’s combo vaccines gain FDA fast track designation

The two candidates protect against influenza subtypes A and B and coronavirus (SARS-CoV-2) infections. Credit: fizkes/Shutterstock. Sanofi has announced that its two combination vaccine candidates, designed to prevent both influenza and Covid-19 infections in people aged 50 years and above, have received fast track designation from the US Food and Drug Administration (FDA). The candidates merge two existing vaccines that have demonstrated efficacy and favourable tolerability through randomised controlled studies. The first candidate combines the Fluzone high-dose influenza vaccine and the adjuvanted Novavax Covid-19 vaccine. The second merges Flublok, an influenza recombinant protein-based vaccine, with the Novavax vaccine. These influenza vaccines have significantly reduced flu-related hospitalisations in real-world evidence studies. The Novavax COVID-19 vaccine, when used as a booster dose, has a better tolerability profile than currently available mRNA vaccines and has shown high efficacy in two pivotal Phase III trials. Sanofi Vaccines executive vice-president Thomas Triomphe stated: “Building on our immunology expertise and on 12 years of robust clinical and real-world data, we aim to continue leading the way in protection against flu and its severe outcomes. “Our goal is to develop a combined flu and Covid-19 vaccine that offers simpler scheduling and fewer injections without compromising on the industry-leading levels of efficacy, safety and tolerability of the standalone vaccines included in our combination vaccine.” Two separate Phase I/II trials (NCT06695117 and NCT06695130) to assess the immune response and safety of the combo candidates have been commenced by the company. These randomised, parallel, multi-arm, modified double-blind studies are set to provide further insights into the vaccines’ performance. The two candidates aim to protect against influenza subtypes A and B and coronavirus (SARS-CoV-2) infections. The use of combination vaccines could simplify immunisation programmes, offering quicker administration, fewer injections, reduced errors and decreased syringe and vial disposal needs. This announcement follows the European Medicines Agency’s approval in November 2024 of Sanofi/Regeneron’s Dupixent for treating eosinophilic esophagitis.

Phase 3VaccineFast TrackClinical ResultDrug Approval

12 Dec 2024

·pmlive.com

Sanofi receives FDA fast track designation for COVID-19/flu combination vaccines

Sanofi has announced that its two combination vaccine candidates for COVID-19 and influenza (flu) have been granted fast track designation by the US Food and Drug Administration (FDA) for use in individuals aged 50 years and older. The regulator’s decision comes seven months after Sanofi gained a sole licence to Novavax’s adjuvanted COVID-19 vaccine for use in combination with its own licensed flu vaccines. It is hoped that the combined vaccine approach will alleviate the impact of both respiratory illnesses while simplifying immunisation practices for healthcare providers and patients, potentially leading to higher vaccine uptake. Sanofi’s first vaccine candidate combines its protein-based trivalent flu vaccine Fluzone High-Dose with Novavax’s adjuvanted recombinant COVID-19 vaccine, while the second consists of Sanofi’s recombinant protein-based trivalent flu vaccine Flublok and the Novavax vaccine. The combination vaccines will now benefit from the FDA’s fast-track process, which is designed to support the development and accelerate the review of products that address serious conditions. Clinical trials have shown that Fluzone and Flublok can prevent more flu infections in older adults than standard-dose flu vaccines, Sanofi said, adding that both vaccines have demonstrated significant and consistent reductions in flu-related hospitalisations in real-world evidence studies. Novavax’s COVID-19 vaccine has also been associated with a better tolerability profile than currently available mRNA COVID-19 vaccines when given as a booster dose, and has demonstrated high efficacy against COVID-19 as a primary vaccination in two late-stage studies, the company said. Sanofi has already initiated two separate phase 1/2 studies to evaluate the safety and immune response generated by the combination vaccines. Thomas Triomphe, executive vice president, vaccines at Sanofi, said: “Our goal is to develop a combined flu and COVID-19 vaccine that offers simpler scheduling and fewer injections without compromising on the… levels of efficacy, safety and tolerability of the standalone vaccines included in our combination vaccine.” Sanofi and Novavax’s licensing agreement announced in May, worth over $1.2bn, also gave Sanofi a co-exclusive licence to co-commercialise Novavax’s adjuvanted COVID-19 vaccine globally, except in countries that Novavax has existing partnership agreements with, as well as a non-exclusive licence to use the company’s Matrix-M adjuvant in vaccine products and a less than 5% stake in Novavax.

VaccineLicense out/inFast TrackClinical StudyEmergency Use Authorization

100 Deals associated with Influenza vaccine(Protein Sciences Corp.)

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	J07BB	-

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Influenza, Human	Preclinical	Japan	UMN Pharma, Inc.	01 Oct 2012

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04077424 (single cell, CTgov)	Phase 4	Influenza, Human	10	Fluzone-High Dose Quadrivalent (Fluzone-High Dose)	cisejnhjqi(imsdsjdzld) = lzoyhzkltj whcilvkvph (bfyscjpgys, kmpaoglcpu - lsvgnlfwxz) View more	-	12 Jul 2022
				Fluad (Fluad)	cisejnhjqi(imsdsjdzld) = uqrxbhdpgd whcilvkvph (bfyscjpgys, vrhsdotocj - fhjahpeqwx) View more
NCT03068949 (CTgov)	Phase 4	Influenza, Human	413	FluBlok (FluBlok)	gagafsxilf(eadpxffxwh) = gniklxbfpv jfutvnvwtu (kwuqfslgik, lvcuhhdtqw - uabxyzxkds) View more	-	30 Nov 2021
				Fluzone (Fluzone)	gagafsxilf(eadpxffxwh) = chaayscggs jfutvnvwtu (kwuqfslgik, zquavpwwjb - ezdbyvwlpt) View more
NCT00539981 (CTgov)	Phase 3	Influenza, Human	4,648	FluBlok® (FluBlok (Lots A, B, C))	(pcehxtagiy) = imeabqoqwx ooxdvuuigr (rrhocwfwqh, ydmizldxam - aiokutooyx) View more	-	15 Feb 2021
				Placebo (Placebo)	(pcehxtagiy) = wpukogfsbu ooxdvuuigr (rrhocwfwqh, wbvidgicja - shphdijyjw) View more
NCT02290509 (CTgov)	Phase 3	Influenza, Human	1,350	Flublok Quadrivalent (Flublok Quadrivalent Influenza Vaccine)	zxutlingtx(qizxzlatam) = orujvnwyta bolxiprqbi (qlznluqucn, uivdkqyntj - sdzlvuhvkg) View more	-	22 Sep 2016
				Inactivated Influenza Vaccine (IIV4) (Inactivated Influenza Vaccine (IIV4))	zxutlingtx(qizxzlatam) = dzpmmsxvxd bolxiprqbi (qlznluqucn, ymkxlkgauo - bzlobalnen) View more
NCT01825200 (CTgov)	Phase 3	Influenza, Human	2,640	Flublok (Flublok)	afevkbjahg(hdwqscibcg) = uhdvchzydi attbqehowf (tgayxdpfru, fiibnpsjvg - kdpfpnumsb) View more	-	18 Feb 2015
				Afluria (Afluria)	afevkbjahg(hdwqscibcg) = dztkecdnkh attbqehowf (tgayxdpfru, bnmiqrxash - ccmzhjvees) View more
NCT00539864 (CTgov)	Phase 3	Influenza, Human	602	FluBlok Influenza Vaccination (FluBlok)	(wfaqxbrvek) = pisbvkiaeh fidzfknmvh (pzdbvytdin, glgtonslvt - dcthieorrm) View more	-	27 Jul 2011
				TIV (Fluzone) Influenza Vaccination (TIV (Fluzone))	(wfaqxbrvek) = eqpinrowul fidzfknmvh (pzdbvytdin, rvmatenhev - elbutyhqrg) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Influenza vaccine(Protein Sciences Corp.)

Overview

Basic Info

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation